On Monday Syndax Pharmaceuticals Inc (NASDAQ: SNDX) was 3.60% up from the session before settling in for the closing price of $9.04. A 52-week range for SNDX has been $8.58 – $25.07.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -15.16% annually for the last half of the decade. When this article was written, the company’s average yearly earnings per share was at -1.15%. With a float of $82.47 million, this company’s outstanding shares have now reached $86.05 million.
In an organization with 270 employees, it is important to assess its efficiency. In terms of profitability, gross margin is -3.44%, operating margin of -786.59%, and the pretax margin is -757.52%.
Syndax Pharmaceuticals Inc (SNDX) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Syndax Pharmaceuticals Inc stocks. The insider ownership of Syndax Pharmaceuticals Inc is 4.16%, while institutional ownership is 115.59%. The most recent insider transaction that took place on May 16 ’25, was worth 105,826. In this transaction Head of R&D, CMO of this company bought 11,765 shares at a rate of $8.99, taking the stock ownership to the 35,165 shares. Before that another transaction happened on May 19 ’25, when Company’s Director bought 5,000 for $8.99, making the entire transaction worth $44,950. This insider now owns 79,000 shares in total.
Syndax Pharmaceuticals Inc (SNDX) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around -1.15% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 27.52% during the next five years compared to -15.16% drop over the previous five years of trading.
Syndax Pharmaceuticals Inc (NASDAQ: SNDX) Trading Performance Indicators
You can see what Syndax Pharmaceuticals Inc (SNDX) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 5.75. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 18.43.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.87, a number that is poised to hit -1.00 in the next quarter and is forecasted to reach -2.67 in one year’s time.
Technical Analysis of Syndax Pharmaceuticals Inc (SNDX)
Let’s dig in a bit further. During the last 5-days, its volume was 2.58 million. That was better than the volume of 2.22 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 32.09%.
During the past 100 days, Syndax Pharmaceuticals Inc’s (SNDX) raw stochastic average was set at 9.38%, which indicates a significant decrease from 22.69% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 41.29% in the past 14 days, which was lower than the 77.46% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $10.91, while its 200-day Moving Average is $14.41. However, in the short run, Syndax Pharmaceuticals Inc’s stock first resistance to watch stands at $9.64. Second resistance stands at $9.92. The third major resistance level sits at $10.28. If the price goes on to break the first support level at $9.00, it is likely to go to the next support level at $8.64. Assuming the price breaks the second support level, the third support level stands at $8.36.
Syndax Pharmaceuticals Inc (NASDAQ: SNDX) Key Stats
There are 86,047K outstanding shares of the company, which has a market capitalization of 805.83 million. As of now, sales total 23,680 K while income totals -318,760 K. Its latest quarter income was 20,040 K while its last quarter net income were -84,850 K.
